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Abstract
Background: Biobanks are precariously situated at the intersection of science, genetics, genomics, society, ethics,
the law and politics. This multi-disciplinarity has given rise to a new discourse in health research involving diverse
stakeholders. Each stakeholder is embedded in a unique context and articulates his/her biobanking activities differently.
To researchers, biobanks carry enormous transformative potential in terms of advancing scientific discovery and
knowledge. However, in the context of power asymmetries in Africa and a distrust in science born out of historical
exploitation, researchers must balance the scientific imperative of collecting, storing and sharing high quality biological
samples with obligations to donors/participants, communities, international collaborators, regulatory and ethics
authorities. To date, researcher perspectives on biobanking in South Africa have not been explored and documented.
Methods: In-depth qualitative interviews were conducted with a purposive sample of 21 researchers – 8 in the
Western Cape, 3 in Gauteng and 10 in Kwa-Zulu Natal. Interviews lasted approximately 40–60 min and were
audiotaped with consent. Thematic analysis of the transcribed interviews was conducted by the co-authors.
Results: Researchers articulated serious concerns over standardised regulatory approaches that failed to consider
the heterogeneity of biobanks. Given that biobanks differ considerably, guidelines and RECs need to stratify risk
accordingly and governance processes and structures must be flexible. While RECs were regarded as an important
component of the governance structure researchers expressed concern about their expertise in biobanking.
Operational management of biobanks was regarded as an ethical imperative and a pre-requisite to building trust
during consent processes. While broad general consent was preferred, tiered consent was thought to be more
consistent with respect for autonomy and building trust. Material Transfer Agreements (MTAs) were often lacking
when biosamples were exported and this was perceived to impact negatively on trust. On the other hand,
researchers believed that authentic community engagement would help to build trust.
Conclusion: Building trust will best be achieved via a system of governance structures and processes that precede
the establishment of a biobank and monitor progress from the point of sample collection through to future use,
including export. Such governance structures must be robust and must include comprehensive national legislation,
policy and contextualised guidelines. Currently such governance infrastructure appears to be lacking in many
African countries including South Africa. Capacity development of all stakeholders including REC members will
enhance expeditious and efficient review of biobanking protocols which in turn will reinforce trust in the
researcher-donor relationship. Science translation and community engagement in biobanking is integral to the
success of biobanking in South Africa.
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Background
Biobanks could be described as a “discursive practice that
is vague and open to articulation because each particular
stakeholder embedded in a particular context articulates
its biobanking activities differently” [1]. Furthermore, bio-
banks are located at the intersection of science, genetics,
genomics, society, ethics, the law and politics. This multi-
disciplinarity has given rise to a new discourse in health
research involving diverse stakeholders.
African genetic diversity lies at the core of the contro-
versy that surrounds data and sample mining. Our
samples are highly sought after internationally and the
unidirectional flow of samples out of Africa has raised
huge concerns around exploitation of vulnerable com-
munities and countries. In an attempt to stem the tide
of sample exportation the Human Health and Heredity
Africa (H3 Africa) project funded jointly by the National
Institutes of Health (NIH) and the Wellcome Trust,
seeks to develop scientific capacity in Africa by en-
couraging African scientists to develop biorepositories
in various African countries including South Africa. If
successful, this venture will present an unparalleled
opportunity for researchers and healthcare in Africa.
Biobanking has become a core resource for medical
researchers as it has enormous transformative potential.
However, researchers must also be mindful of the intri-
cate web of ethical and social complexities inherent in
the collection, storage and future use of biospecimens,
especially in Africa, given the power asymmetries at play
in international collaborative research relationships and
a historical context of exploitation. Public opinion is
cautious and trust in medical research in South Africa
is waning. This crisis in trust has been fuelled by a his-
tory of exploitation in medical research that exploits
vulnerabilities of developing world communities. It is
also fuelled by the deep cultural significance that South
African communities attach to blood and other bio-
logical samples [2].
Although most literature on ethical concerns related
to biobanking focuses on consent [2–6], other concerns
such as governance, community engagement, inter-
national collaboration and sample sharing are relevant
[6–10]. Furthermore, several stakeholders are central to
biobanking and eliciting their multiple and diverse per-
spectives is important. Previous studies on biobanking
have explored participant [2, 10], REC member [11],
patient [12] and media perspectives [13]. Some papers
have explored the views of researchers who collect and
use samples in resource rich countries [14–20]. To date
there has been no published empirical work on researcher
perspectives on biobanking in Africa. Consequently, this
qualitative study was undertaken to explore perspectives
of researchers working with biospecimens and/or bio-
banks in South Africa.
Methods
In-depth qualitative interviews were conducted with 21
researchers – 8 in the Western Cape, 3 in Gauteng and 10
in Kwa-Zulu Natal. Most researchers (12) were male and
9 were female. Respondents were medical and scientific
researchers, biobanking experts and governance experts
working across different disciplines: virology, haematol-
ogy, immunology, pathology, HIV and Tuberculosis.
Purposive sampling was used to identify researchers for
the individual face-to-face in-depth interviews. An
interview schedule was designed to elicit participants’
understanding and opinions of ethical considerations in
the use of biological material for research purposes and
biobanking in particular (Additional file 1). The guide
was based on existing literature [1–10, 15–19].
For the recruitment strategy, all identified researchers
were contacted via email, as an introduction to the
proposed study. The principal investigators thereafter
set up face-to-face interviews based on the participants’
availability and willingness to participate in the study
(Additional file 1). The consent process was conducted
verbally and in writing. Interviews were digitally recorded
and lasted an average of 30–45 min. The interview schedule
comprised open-ended questions that focused on the fol-
lowing broad areas: scientific and ethical concerns about
biobanking; governance; informed consent; data and sample
management, export and sharing. Interviewees were also
given the opportunity to make recommendations for the
use of biological material in South Africa and to provide
policy inputs for the National Health Act (No. 61 of 2003).
During the data analysis process, audio-recorded interviews
were first transcribed verbatim and a data clean-up process
was applied. The narrative from each interview transcript
was subjected to thematic analysis [21]. Both interviewers
(KM and SS) read through the transcripts to extract themes
(analyst triangulation). The data were analysed by the two
authors independently and then integrated via discussion.
Results
Seven main themes emerged from the data. The compe-
tence of RECs in reviewing biobanking protocols was a
common concern. A careful analysis of the risks and
benefits of biobanking was regarded as a prerequisite to
considering other ethical issues. Amongst these, consent
emerged as a contentious and unresolved issue. Govern-
ance was regarded as a multi-layered concept with na-
tional guidance and regulations often poorly developed.
Likewise, the absence of Material Transfer Agreements
made export of samples challenging even on the African
continent. Most participants agreed that sound oper-
ational management and sustainability of biobanks was
an ethical imperative. Finally, community engagement
was regarded as a critical process to build trust. Each of
these themes is discussed in detail.
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Research ethics committee competence
As a point of departure, researchers interviewed in this
study all referred to the heterogeneity that exists in the
field. They explained that biobanks may range from
small collections of disease specific blood and tissue
samples to large scale general population based collec-
tions of blood exceeding a million samples.
Different environments maintain specific biobanks…
“study specific biobanks so it’s not a biorepository in the
true sense of the word”.
“Virology keeps biobanks for 3 reasons: for diagnostic
purposes, to validate tests and to introduce or
evaluate a new diagnostic method with samples such
as for Viral Load monitoring. However if we later
want to do resistance testing, consent has not been
obtained. We can get a waiver of consent via the
REC for anonymised samples but if we anonymise
we lose value to individual patients – the REC may
not understand this”.
Others commented that RECs must be able to under-
stand heterogeneity of biobanks and stratify the review
according to the risks related to volume and type of
specimens handled. Many researchers felt that RECs
needed to take heterogeneity of biobanks into account
in decision-making and governance. There were also
concerns about careful risk-benefit calculations in REC
deliberations.
Risk-Benefit ratios in biobanking
Researchers were sensitised to the risk-benefit calcula-
tions that precede regulatory decision-making in bio-
banking. They distinguished between individual benefit
and public health benefit. Most of the respondents
were extremely confident about the scientific and clin-
ical benefits inherent in biobanking. With HIV viral
load samples one can later look for resistance, neutra-
lising antibodies or mutations associated with anti-
retroviral treatment failure. However, this potential
individual benefit for the patient is lost if samples are
anonymised obviating the need for re-consenting par-
ticipants for future use of samples. On the other hand,
with some diseases, public health benefits are great,
hence an opt-out system of consent or waiver of con-
sent would be justified. A distinction was also drawn
between short term and long-term benefits. Prospect-
ively biobanking high quality samples with associated
data in a retrievable manner will have an enormous
impact on streamlining and accelerating medical scien-
tific research in the future:
“We are banking for the future…the benefit in all this
is for the next generation.”
“I don’t know what the research question is going to
be therefore I must bank in such a way that I can ask
any research question in the future.”
A number of risks were identified. This included the
concept of over-researched communities:
“There is competition for participants by different
research groups…there are actually not enough TB
[Tuberculosis] patients in Cape Town for the number
of research projects. It’s over researched. People are
fighting over TB patients. There is competition
between basic science and clinical trial research. Some
patients are selling sputum outside the clinic, so that
negative patients can enrol to get a box of biscuits or
a grocery voucher”.
Concern was expressed over the prospect of commer-
cialisation which was regarded as a significant risk. In
particular, respondents argued that selling samples to a
pharmaceutical company should not be allowed:
“Human tissue is this untouchable Holy Grail that you
can’t mess around with, you cannot abuse it, you
cannot sell it, and you cannot make a profit out of it.”
Infectious disease specimens were regarded as a risk
to biobank staff and patients alike. The need for robust
infection control measures in biobanks was stressed.
An important benefit reported in the field of infectious
disease was that super- spreaders of HIV could be identi-
fied….sequence data could reveal the patient even if the
sample were to be anonymised. Researchers therefore re-
ferred to the “myth of anonymity”. While this researcher
mentioned the identification of super-spreaders as a
benefit, this benefit referred to preventing further spread
of HIV in an attempt to control the epidemic. Deliberate
transmission of HIV has not been criminalised in a
specific law in South Africa. However, biobanked speci-
mens could potentially be used in a legal investigation,
if required by the courts.
Finally, stigma associated with genetics and genomics
research was regarded as a specific risk to patients making
genetic and genomic biobanking more challenging.
Concerns around such risks and benefits would need to
be included in consent processes.
Preferred consent models
Discussions around consent ranged from broad consent
to tiered consent with one researcher referring to dy-
namic consent. Most researchers indicated a preference
for one time broad consent that would allow future use
of samples. Re-consenting participants was regarded as
impractical and resource intensive:
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[We have to] “balance the time and effort spent on
consenting versus time spent on research”
“It would cost millions to re-consent participants…is
it more unethical to keep samples or destroy them?”
“Reasonable efforts are made to contact patients… but
in practice this is difficult because mobile telephone
numbers change and patients relocate frequently
[in South Africa].”
Some researchers/scientists who work closely with
clinicians expressed concern about the sustainability of
detailed consent processes:
“Clinicians feel they have the trust of patients and
would like to obtain consent – whether that’s a
sustainable option remains to be seen. The consent
form is rather comprehensive and it will take time.
While clinicians may initially speak to patients to get
their agreement, formal consent can be obtained by a
nurse, scientist or technologist from the biobank who
is trained to do the consent”.
On the other hand, researchers working with indigenous
populations in Southern Africa were quite confident that
some communities would not subscribe to broad consent:
“…the San Council would not give broad consent,
they would only give fairly narrow specific consent
but they would not be averse to re-consenting if there
was something worthwhile to be done”.
A tiered consent model which included specific con-
sent and broad consent would be applicable in such
cases and would increase trust as choices are provided
to participants.
Citing technological advances as a means to improve
consent processes, one researcher explained how
“we are moving to the era of dynamic consent and
dynamic participation…with the age of technology…
that’s possible. You will receive constant notifications
on your cell phone that your samples have now been
created into cell lines or they have been submitted to
a pharmaceutical company who are now creating a
new drug.”
Moving away from models of consent, some researchers
expressed concern about the actual information contained
in consent forms:
“Consent forms should evolve in consultation with
Community Advisory Boards so that the consent
form can actually contain the information that
would be really important from the patient and
community perspective.”
“At the moment the consent form is the product
of the researcher/research team and biobank
perspectives… it contains literature from an ethics
and legal perspective…it may not be important from
the patient’s perspective.”
While many researchers believed that anonymization of
samples could impede return of individual results to par-
ticipants others referred to the “myth” of anonymization:
“Withdrawal of samples and return of results, even if
samples were anonymised, would be possible using
genetic signatures. H3Africa is working on a SNP
profile for African ethnic groups.”
Multiple levels of governance is imperative
Collectively, our respondents contributed different aspects
of governance to the discussion around biobanking.
“Governance structures are multi-tiered…international
bodies like WHO and United Nations, WMA…
Helsinki. Then you have societies like ISBER and
ESBB and high level governance structures with
guidelines and policies. On the continent, the African
Union and SADC region policies. Nationally, South
African policy…Department of Health…University
policies…a microenvironment of board members and
trustees and community engagement”.
Some respondents were critical of the existing legisla-
tion in South Africa with respect to biological samples:
“The lack of regulatory standards is a problem and
legislation has not really been quite clear on biobanking
research”. [The] “definition of tissue is problematic and
excludes plasma which has no cells so is excluded from
the legislation but plasma may have viruses”.
The tissue banking legislation has been written for
therapeutic biobanks – bone banks, stem cell banks,
heart valves, gametes, corneas…. these are different from
research biobanks.
“Biobanks and tissue banks are not the same thing. We
need a separate set of regulations for biobanking which
could fall under chapter 8 of the National Health Act”.
Although the REC was seen as a governance structure
by most researchers, some commented that biobanking
protocols are
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“evaluated by people who are not experts within the
field and do not know the implications of what we are
doing….people who do not differentiate between viral
genomics and human genomics…we need expert panels
that have expertise to review biobanking protocols”.
Finally, some researchers contended that we need to
conduct an audit at a national level:
“…we need to go around and find out where the
biobanks are, how have samples been stored, make
sure ethics approvals are appropriate, is there a global
unrestricted use of samples….we will have to look at
the governance structures.”
In this respect there was considerable discussion
around governance involved in the export of samples.
Export and Material Transfer Agreements (MTAs)
Discussions around export of samples and MTAs elicited
strong opinions. Researchers insisted that patients must
be informed that their samples will be sent to the United
States (US) and/or Europe with contracts, MTAs and
export permits. A significant concern related to the lack
of a national MTA in South Africa.
“MTAs are drawn up by the legal department. The
samples cannot be handed over to anybody but there’s
no way I can monitor what they do with the samples.
We send it based on trust. Some researchers in
Europe and the US try to bully us….they think all
African institutions are backward and they are not
very respectful towards the sample providers. They are
quite taken aback when we actually insist on an MTA.”
Preventing unilateral drift of samples out of Africa and
retaining intellectual property rights on the continent
was generally regarded as important. With respect to the
H3Africa project and the African Malignancy Consor-
tium (AMC), the “biobank will provide specimens to
researchers from anywhere in the world with an ap-
proved research protocol….but the Principal Investigator
or co-PI must be from the African continent”.
However, even moving samples within the continent is
challenging as some African countries have MTAs while
others do not. Legislation with respect to export differs
from one country to the next making cross-border
transfer of samples almost impossible. This was regarded
as important enough to erode trust in biobanking.
Operational management and sustainability of biobanks
as ethical imperatives
Infrastructure and security needs are considerable for
biobanking. Researchers highlighted the critical need for
electricity and back-up power supplies. If a biobank collec-
tion of samples is housed in two different buildings, two
generators are required. In South Africa in recent times
“with power interruptions and load-shedding the
generator came on but did not deliver power and
that led to a huge crisis. Five of the ten freezers
broke down, each freezer costs R120 000 (about US
$10 000)….you can recover reagents but not samples
and samples cannot be insured. So we got a 24 h
surveillance system to monitor the temperature and
a whole team that is available 24 h a day, every day
of the year, to monitor our freezers”. Operational
costs are high “it costs R1.25 per sample per month
to store a sample in a -80° Celsius freezer and double
that (R2.50) to store in liquid nitrogen”.
Retrieval systems must be optimised. Lost samples
were regarded as a violation of promises made to par-
ticipants during consent processes.
“You’ve got to have buy in from your participants…
and colleagues because biobanking is very expensive.
If you are going to make biobanking worthwhile then
you must introduce the concept of centralised
banking in institutions or regions”.
Sustainability of a biobank requires stable and con-
tinuous income streams and reliable funding sources.
Respondents expressed strong concerns that lack of
robust operational management of biobanks would
result in wasted samples and abandoned, liquidated or
sequestrated biobanks in financial distress. This would
most certainly undermine donor trust. Integrity and
quality of samples, good business practice and govern-
ance were regarded as non-negotiable ethical require-
ments for biobanking.
Community engagement as a research priority to build trust
Researchers were unanimous about the value they placed
on community engagement as a pre-cursor to building
trust.
“We have to take participants along with us. That
involves an extensive amount of engagement involving
them in empirical research: what are their views and
opinions? What are their cultural issues around
biobanking and the cultural issues around the use of
tissue and the movement of tissue to other countries
and into the commercial space?”
Generally, researchers emphasized the meaning that
cells, blood, tissues and organs held culturally and this
had to be explored with participants and patients:
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“If we are going to create cell lines, you know the
whole African concept about your spirit lives in
your cells, your cells are still alive and when I die
I want my cell lines to be brought back. Once your
cell lines have gone, they are gone. You can’t ever
bring them back.”
In particular, a few of the respondents in this study
shared their experiences in working with indigenous
communities such as the San communities in Southern
Africa:
“With the San community, researchers must first
meet with community leaders, get to know them,
build trust and then, in the presence of community
leaders explain to the community what it is that one
is aiming to do and then get the community to vote…
once the community agrees then you have to explain
to individual participants and get individual consent.
After the study you need to go back to the
community, first to community leaders to explain
the implications of your findings, then explain to
the community”.
Benefit sharing was expressed as follows: “if one could
contribute to the education of the San community by
building a school or providing bursaries to send people
to university then I think that is fine. That’s a form of
benefit sharing.”
Various suggestions on how to engage with commu-
nities were proposed - community newspapers, educa-
tional videos, strong advocacy groups that would
“ensure good representation and trust”. You have to
engage in widespread community activity whereby the
community knows what you are doing and are reas-
sured about the integrity and trust, “because it’s all
about trust”. In addition, annual feedback to the com-
munity was regarded as essential.
Concern was expressed that funding of community
engagement is still too low and that researchers and
funders need to include this as a separate budget item
in grant applications.
Discussion
Some of the concerns raised in this study of researchers
echo findings in other studies from resource rich environ-
ments. However, many concerns deviate significantly.
The most striking sub-theme underlying the major
themes that emerged in this study was the importance
of building trust with communities. In some countries
biobanks are being established in a “context of height-
ened concerns” about a “decline in trust” in scientists,
authorities and experts in the regulatory systems governing
biotechnology innovations [22]. Recently the tension has
been exacerbated by participants exercising individual
and group autonomy and demanding return of their
blood specimens [23]. Several authors cite trust as a
central component of the research participant-
researcher relationship [2, 24–26]. In developing coun-
tries, failure to engage with communities has been
identified as a reason for erosion of trust in researchers
[27]. Similarly, Barchi et al., in their study on REC
members in Botswana, identified lack of trust as a sig-
nificant challenge and also cite failure to engage with
communities as a cause of the erosion of trust [11].
Dilution of trust in the researcher – donor relationship
may occur when samples are exported for unknown
future use in foreign countries [28]. Respondents in this
study concurred that trust underscores all biobanking
endeavours and is critically predictive of success.
Governance of biobanks will require understanding of
the “immense diversity found in organizational features”
[29]. Considerable heterogeneity exists in the field and
biobanks may range from small collections of disease
specific blood and tissue samples to large scale general
population based collections of blood and other tissue.
Respondents in this study identified the dissonance
between the type of biobank, the nature of proposed
research and the ability of REC members to appreciate
the risk. This was perceived as a major obstacle to
obtaining approval.
A standardized approach in reviewing all protocols
involving biobanks in the same way has the potential to
lead to generalization of risks and over-regulation of re-
search. They argued that it is important for RECs to be
able to stratify risk according to type of biobank being
proposed or used. Small, local, non-communicable dis-
ease specific biobanks (such as exist for hypertension or
diabetes) within institutions tend to use stored samples
for specific research limited to that disease area in the
future. If patients have consented to such specific future
use, such research carries lower risk than a project in-
volving the collection of large volumes of specimens
from healthy participants for undefined broad future use
including export to other countries.
Similarly, specimens collected in the context of highly
infectious disease outbreaks such as Ebola carry higher
risk in terms of risk to biobank personnel, transporta-
tion, export and security risks. Often small collections
of samples are over-regulated while large-scale biore-
positories and sample collections that are potentially
infectious are under-regulated. Thousands of speci-
mens left West Africa during the recent Ebola out-
break and the fate of these specimens is still unclear
and unregulated [30].
Many respondents in this study expressed frustration
about the decisions made by RECs based on a lack of
understanding of biobanks and the potential future use
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of biospecimens in research. Similar frustration was
expressed by researchers in the United Kingdom who
participated in 4 focus group discussions (FGDs) in
2011. In fact, in that study, the challenges experienced by
researchers with regulatory bodies was the most striking
finding that emerged from the FGDs. These challenges
were exacerbated in international studies where sharing of
samples and data across borders was involved. In such
studies the REC approval process was considerably length-
ened [16]. Such concerns have been raised in previous
publications examining governance in Africa [8, 9]. Like-
wise, in our study, the lack of a national MTA in South
Africa and in other African countries was regarded as
holding the potential to seriously delay biobanking and
biobanking research on the continent and to undermine
trust in international studies.
At a national level in South Africa, governance was
cited as an obstacle due to regulations that are not suffi-
ciently comprehensive and even absent in the arena of
biobanking for research. This concern echoes findings in
previous publications [8, 9]. The South African research
ethics regulatory structure comprising a National Health
Research Ethics Council (NHREC) with an oversight and
accreditation function over the 33 RECs registered with
it, requires that the national body establish guidance on
biobanking review and capacity development of REC
members in this field. It is also the obligation of the
NHREC to strongly motivate, via the Department of
Health, for the development of legislation on biobanking
in South Africa. Likewise, selection of REC members in
South Africa must be reviewed with attention devoted
to expertise, research experience and commitment to
research ethics review. Training opportunities for REC
members have been repeatedly emphasized yet this
often remains a neglected issue at an institutional level.
Given the low levels of science literacy in South Africa
and the challenges posed in consent processes for a wide
range of research, consent for biobanking was promin-
ently discussed by respondents in this study. In keeping
with published studies on researcher perspectives which
reflect a preference for broad consent with open-ended
future use [19], the respondents in this study strongly
supported broad consent. This finding was echoed by
Whitley et al. where broad consent was preferred due to
the challenges posed by predicting future research use
[16]. However, many respondents reflected a deep concern
for the principle of respect for persons by suggesting flexi-
bility in consent options, engaging with communities and
respecting cultural contexts and norms, especially of indi-
genous populations. There was a sensitivity to previous
exploitation of research participants in Southern Africa
and the consequent enforcement of rules in specific
indigenous communities as a protective measure. The
approach of community consultation for research
required by the San Council in Southern Africa is
unique in the context of research ethics review systems
in the country that are based on a more individualized
approach to personhood. It is however important to
note that community consent will not replace individual
consent. The San Council views the two levels of the
consent process as complementary.
Few previous studies have explored dynamic consent
where participants are able to liase with a biobank on a
long-term basis using a mobile application and give in-
put on future use of their donated biospecimens [16].
However, researchers proposed this as a strategy to build
trust in South Africa given our large mobile phone net-
work and the possibility of using mobile applications to
engage biobank donors in discussions around future use
of donated biospecimens. It could be argued that dy-
namic consent carries the potential to erode privacy.
However, engaging with biobank donors in this manner
will involve the creation of secure platforms to ensure
confidentiality to the extent possible and privacy will
also respected. Donors will be contacted discretely and
only when absolutely necessary. Despite the convenience
of broad consent to researchers and biobanking custo-
dians, a significant proportion of research participants
surveyed in South Africa have articulated a desire to be
consulted on future use of their samples [10]. Tiered
consent affords research participants the opportunity to
make this choice while dynamic consent allows for im-
plementation of this choice.
This expressed need to involve biobank donors in
decision-making could be a response to the claim that
the traditional science-society relationship premised
upon a “clear separation between expert and lay know-
ledge” has been exposed in biobanking [22]. Respon-
dents in this study were acutely aware of the need to
bridge this gap by engaging with communities to facili-
tate consent processes in biobanking. Various sugges-
tions were made to ensure science translation and
some of these community engagement tools have been
described elsewhere [31]. However, involving patients
as active partners in biobanking, deliberative democracy
activities with communities [31] and patient led bio-
banks [12] were not mentioned. Even though such mea-
sures have been implemented in the United States and
Europe, the authors caution that it was not without
challenges including financial and human resources
[12, 30]. Implementing such a “cultural revolution in
health research” [12] in South Africa is to be encour-
aged. However, significant education of educationally
disadvantaged communities is a precursor to this in-
tense level of public engagement. It is unclear if new
models of public engagement will change the asymmet-
rical power relations between researchers/scientists and
civil society [22] in South Africa.
Moodley and Singh BMC Medical Ethics  (2016) 17:57 Page 7 of 9
Finally an important and repeated comment in this
study was the “myth of anonymization”. While RECs
viewed anonymization as protective of participant rights
to privacy, technological advances in genetics and gen-
omics may make anonymization impossible. Biobanking
is widely cited as having the potential to create ethical
concerns. Privacy is a prominent concern voiced by
donors. It is imperative that the question of coding and
anonymization be addressed so that consent processes
are not perceived as misleading and hence a barrier to
the development of mutual trust between researchers/
scientists and civil society.
Although this is the first study in South Africa to re-
flect the perspectives of researchers, it has surveyed
respondents in 3 regions only. Future research that
casts the net more widely in a geographic sense has
the potential to increase generalisability of the study.
Surveys in other African countries will also yield inter-
esting comparative data. Given that this is the first
survey of researchers in South Africa, a wide range of
concerns was raised in this study. Future research
could narrow the focus to examine some of these
issues in greater depth. In particular, benefit sharing
was briefly mentioned with respect to indigenous
communities. However this represents a study in its
own right and could potentially be explored especially
in resource poor settings. Likewise the myth of ano-
nymity should be further explored.
Conclusion
Given the history of exploitation in South Africa as a
result of apartheid and colonialism and given the general
lack of trust of scientists, building trust will best be
achieved via a system of independent governance struc-
tures and processes that precede the establishment of a
biobank and monitor progress from the point of sample
collection through to future use, including export. Such
governance structures must be robust and must include
national legislation, policy and contextualised guidelines.
Currently such governance infrastructure appears to be
lacking in many African countries including South Africa.
Capacity development of all stakeholders including REC
members will enhance expeditious and efficient review of
biobanking protocols which in turn will reinforce trust in
the researcher-donor relationship. All efforts to improve
trust will lead to enhanced legitimacy of biobanking in
South Africa. Establishing relationships with international
collaborators based on trust, equity and integrity is also
critical for sharing of samples and data.
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